Skip to main content
Erschienen in: Reactions Weekly 1/2017

01.06.2017 | Case report

90Y-DOTATATE/iobenguane/octreotate-Lu-177-DOTA-Tyr-3

Various toxicities: 6 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (FDA MedWatch definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * requires intervention to prevent permanent impairment or damage
Literatur
Zurück zum Zitat Nastos K, et al. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. Journal of Surgical Oncology 115: 425-434, No. 4, Mar 2017. Available from: URL: http://doi.org/10.1002/jso.24553 - United KingdomCrossRefPubMed Nastos K, et al. Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas. Journal of Surgical Oncology 115: 425-434, No. 4, Mar 2017. Available from: URL: http://​doi.​org/​10.​1002/​jso.​24553 - United KingdomCrossRefPubMed
Metadaten
Titel
90Y-DOTATATE/iobenguane/octreotate-Lu-177-DOTA-Tyr-3
Various toxicities: 6 case reports
Publikationsdatum
01.06.2017
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2017
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-017-31345-z

Weitere Artikel der Ausgabe 1/2017

Reactions Weekly 1/2017 Zur Ausgabe

Case report

Bromocriptine

Case report

Gemcitabine

Case report

Sugammadex